Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...

Servier isn’t the first drug developer to spot a silver lining in Google Cloud. Ginkgo inked its own five-year partnership in ...

Avacta is stepping up development of its peptide-drug conjugate (PDC), kicking off expansion cohorts in multiple tumor types ...

Take a look back at the biggest stories of the week with Fierce Biotech’s conference's kickoff coverage here | Welcome to day ...

Serina Therapeutics is shedding a subsidiary to start the new year off debt-free. | Serina Therapeutics is shedding a ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

The FDA is elevating a recall from Philips related to one of its wearable outpatient heart monitors, used to help detect ...

Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell ...

After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have ...